Exonate, an mRNA therapy company focused on treatments for diabetic complications, has announced that its lead ophthalmology asset, EXN407, has achieved its prespecified endpoints in an early study.
Convatec Group, a medical products and technologies company focused on chronic conditions, has partnered with Tandem Diabetes Care on a new five-inch infusion set for Tandem Mobi, the world’s smallest durable automated insulin delivery system.
The company has added Type 2 diabetes to the list of conditions it simulates in it’s A Life in a Day program, enabling people to spend a day living as if they have the disease.
CRISPR Therapeutics and ViaCyte, Inc. have received the green light from Health Canada for their Clinical Trial Application for VCTX210: an allogeneic, gene-edited, immune-evasive, stem cell-derived therapy for the treatment of type 1 diabetes (T1D)....
The pharmacy company's Wegovy (semaglutide) is the first therapy designated for chronic weight management that the agency has granted approval since 2014.
Conducted by SubjectWell, the survey of patients with Type 2 diabetes reveals how ethnicity and other factors play a part in trial participation tendencies.
The two companies have joined forces to collaborate on the commercial launch of Gimoti, a nasal spray for patients suffering from diabetic gastroparesis.
Abbott’s glucose sensing technology and a tubeless insulin delivery system developed by Insulet are set to create a personalized diabetes management solution.
While exhibiting its offering in self-administration devices at the CPhI Worldwide event in Frankfurt last week, West told us how patient convenience drives design and development.
Novo Nordisk completes the construction of a wastewater treatment plant in Clayton, North Carolina, which will be donated to the city to aid biopharma growth.
While the prevalence of chronic diseases boosts the demand for self-administered treatments, ease of use is becoming more important in device manufacturing, says product specialist.
Aptar’s needle-free, emergency powder formulation treatment for patients with diabetes and severe hypoglycemia is the company’s first combination drug delivery device with active packaging.
MannKind Corporation, of Afrezza fame, and United Therapeutics have signed an exclusive licensing and collaboration agreement for dry powder pulmonary hypertension products.
A recent FDA Advisory Committee vote could allow researchers to use continuous glucose monitoring (CGM) systems in place of traditional methods, providing “a myriad of customized data,” says Quintiles.
Patient recruitment specialist Acurian has hit a major milestone in its business, with more than half of the entire US population of type 2 diabetics now opted into its database.
A new class of diabetes drugs is showing promising clinical
results, with the big players in the field all scrapping it out for
a slice of the potential rewards.
Innovative, non-invasive new ways of delivering insulin are poised
to transform diabetes management, despite concerns about their
safety and efficacy, according to new research.
The Servier Institute and Pasteur-Weizmann Council has awarded its
annual prize in biomedical research to two scientists for their
work in diabetes and autoimmunity, paving the way for improved
treatment and an eventual cure for this...
Bang & Olufsen Medicom has unveiled a new disposal
breath-actuated inhaler which uses a reservoir technology that
reduces the daily cost of pulmonary drug delivery.
Diabetes experts have warned that urgent action needs to be taken
to drastically improve the management of diabetes to prevent a
potentially devastating and costly global burden.
Scientists believe they have made a major breakthrough in a
potential cure for diabetes after animal experiments using a
combinatorial treatment approach reversed onset type 1 diabetes.
New diabetes trials scheduled to start this spring have been
heralded as groundbreaking as researchers aim to reverse juvenile
diabetes of which numbers have been steadily on the rise in
developed nations.
Biotechnology company, Amgen, and Biovitrum have expanded its
existing license agreement for its treatment of metabolic
disorders, focusing on type 2 diabetes, which currently afflicts
over 160 million people worldwide.
UK scientists think that diabetes patients could be able to receive
insulin via a nasal spray using yeast, which would open up the way
for a spray to be developed to replace injections.
Canadian biotech company Generex has begun a study of its flagship
oral insulin spray in patients with Type-1 diabetes. The product,
already available for type 2 diabetes in Ecuador, was the first
non-injectable form of insulin to...
New insights into the dysregulation of beta cells and their impact
on type 2 diabetes progression is now possible after Roche
announced a partnership, which aims to identify novel pathways and
new biomarkers for drug development.
Generex Biotechnology announced its Oral-lyn, the first
non-injectable form of recombinant human insulin available for
commercial distribution anywhere in the world is being launched in
Ecuador to soon become available through physician...
Researchers are developing breakthrough diabetes drugs that use
modified forms of a naturally occurring molecule produced by the
body. The approach characterises the major investments by the
biopharmaceutical industry to develop and...
Merck Sharp & Dohme (MSD), the UK subsidiary of Merck & Co
of the US, is to partner with the European Foundation for the Study
of Diabetes (EFSD), to further explore a novel area of diabetes
research.
According to a new report, the global diabetic population is set to
double by 2030, with treatments currently falling way short of
medical needs. The focus falls on impending products offering novel
therapies to diabetics and for...
The limited efficacy of existing diabetes therapies is set to pose
the main challenge for the European diabetes diagnostics markets as
the uptake and adoption for new innovative techniques determining
the future of this burgeoning...
Biovitrum and Santhera have announced the signing of an exclusive
license and collaboration agreement, which aims to develop DPP-IV
inhibitors for the treatment of type 2 diabetes and other metabolic
diseases.
The latest research included in the proceedings of the annual
scientific meeting of the American Diabetes Association (ADA) means
that diabetic treatments and other therapies for the disease
feature strongly in DrugResearcher's...
